Immix Biopharma, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing sterically-optimized chimeric antigen receptor T-cell (CAR-T) therapies targeting relapsed/refractory light chain (AL) amyloidosis and other immune-mediated serious diseases. The company offers NXC-201, its lead investigational BCMA-targeted autologous CAR-T therapy from the proprietary N-GENIUS platform featuring EXPAND technology, which has demonstrated high complete response rates, absence of neurotoxicity, and enhanced tolerability in ongoing Phase 1b/2 NEXICART-1 (NCT04720313) and NEXICART-2 (NCT06097832) trials; IMX-110, a tissue-specific therapeutic in Phase 1b/2a for solid tumors including soft tissue sarcoma and colorectal cancer under a clinical collaboration with BeiGene Ltd. involving anti-PD-1 tislelizumab; and preclinical assets addressing autoimmune conditions such as inflammatory bowel disease. Founded in 2012 and headquartered in Los Angeles, California, Immix Biopharma conducts operations in the United States and Australia with U.S. FDA and EU orphan drug designations for NXC-201 in AL amyloidosis and multiple myeloma, plus recent FDA Regenerative Medicine Advanced Therapy designation. Recent developments include surpassing 50% enrollment in NEXICART-2 ahead of schedule with plans for a Biologics License Application submission, strategic investment from Goose Capital led by Dr. Nancy T. Chang who joined the board, positive interim data presentations at ASCO 2025 and ASH 2024 showing 75% complete response rates in heavily pretreated patients, expansion of U.S. trial sites to 14 active locations, and announcements of partnerships for other serious disease programs.
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
Brokerages Set Immix Biopharma, Inc. (NASDAQ:IMMX) Price Target at $18.25
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Immix Biopharma (IMMX) to Release Earnings on Monday
Immix Biopharma to Participate in Upcoming Investor Conferences
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting